AI assistant
Sending…
Passage BIO, Inc. — Director's Dealing 2022
Apr 20, 2022
34849_dirs_2022-04-20_65ad0613-36de-4f5e-91f6-742d417a40da.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Passage BIO, Inc. (PASG)
CIK: 0001787297
Period of Report: 2022-04-18
Reporting Person: Forman Mark S (Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-04-18 | Employee Stock Options (right to buy) | $2.61 | A | 136000 | Acquired | 2032-04-17 | Common Stock (136000) | Direct |
Footnotes
F1: The stock option vests as to 25% of the total shares on April 18, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
More from Passage BIO, Inc.
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 26
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 7
Proxy Solicitation & Information Statement
2026
Apr 7
Director's Dealing
2026
Mar 18
Annual Report
2026
Mar 3
Regulatory Filings
2026
Mar 3